Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Lung cancer nanomedicine: Potentials and pitfalls.
Nanomed. 10, 3203-3212 (2015)
Lung cancer is by far the most common cause of cancer-related deaths in the world. Nanoparticle-based therapies enable targeted drug delivery for lung cancer treatment with increased therapeutic efficiency and reduced systemic toxicity. At the same time, nanomedicine has the potential for multimodal treatment of lung cancer that may involve 'all-in-one' targeting of several tumor-associated cell types in a timely and spatially controlled manner. Therapeutic approaches, however, are hampered by a translational gap between basic scientists, clinicians and pharma industry due to suboptimal animal models and difficulties in scale-up production of nanoagents. This calls for a disease-centered approach with interdisciplinary basic and clinical research teams with the support of pharma industries.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Active Targeting ; Clinical Studies ; Lung Cancer Therapy ; Nanomedicine ; Nanoparticle ; Tumor Mouse Model
ISSN (print) / ISBN
1743-5889
e-ISSN
1748-6963
Journal
Nanomedicine
Quellenangaben
Volume: 10,
Issue: 21,
Pages: 3203-3212
Publisher
Future Medicine
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Lung Health and Immunity (LHI)